Category: tools-profils-members

Vice President and Chief Scientific Officer (CSO)   Maurizio Ceppi joined Transgene in September 2024 as Vice President in charge of Research and Development (Chief Scientific Officer – CSO). With over 15 years in the oncology life sciences industry, he holds a deep expertise in cancer immunotherapy and precision medicine. Throughout his career, Maurizio Ceppi… Continue reading Maurizio CEPPI, PhD

VP Medical Affairs & Chief Medical Officer (CMO)    Emmanuelle Dochy, MD, joined Transgene in September 2024 as Chief Medical Officer (CMO). Emmanuelle Dochy was previously Vice President of Global Medical Affairs at Bayer, where she gained extensive experience in managing medical affairs on a global scale. With 15 years of experience in the pharmaceutical… Continue reading Emmanuelle DOCHY, MD

VP, Corporate Communication and Investor Relations Lucie is appointed on March 27 as Chief Financial Officer, responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Since 2016, Lucie has served as Director Corporate Communications and Investor Relations, reporting to the CEO and joins… Continue reading Lucie Larguier

Director Michel Baguenault de Puchesse has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human… Continue reading Michel Baguenault

Scientific advisor   John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically… Continue reading John C. Bell, PhD

Scientific advisor    Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer. Previously,… Continue reading Pedro Romero, MD

Independent Director  Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of… Continue reading Carol Stuckley

Independent Director, Chairman of the Clinical Development Committee  Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads… Continue reading Prof. Jean-Yves Blay

Chairman and CEO Dr. Riva has nearly 30 years’ experience in the Life Sciences industry.  He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at… Continue reading Dr. Alessandro Riva

MD, Independent Director Laurence Zitvogel, MD, is a professor of immunology and biology at Paris University (Université de Paris Saclay). An oncologist and researcher at Institut Gustave Roussy since 1995, she is internationally renowned for her work in anti-tumor immunology; she has led Phase I and Phase II clinical studies in cancer immunotherapy and deciphered… Continue reading Dr. Laurence ZITVOGEL